TNF and psoriasis: Most pharmacogenetics studies on anti-TNF drugs were designed following a candidate-gene approach, i.e., analyzing a reduced number of genes previously associated with psoriasis or biological drug response [12,24,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44].